Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.24 NOK | +2.00% | +0.61% | -38.13% |
Business Summary
Number of employees: 172
Sales per Business
NOK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Vaccines and Immunotherapies
100.0
%
| 292 | 100.0 % | 69 | 100.0 % | -76.39% |
Sales per region
NOK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 292 | 100.0 % | 69 | 100.0 % | -76.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Chief Tech/Sci/R&D Officer | 50 | 21-05-31 | |
Chief Tech/Sci/R&D Officer | - | 17-07-31 | |
Siri Torhaug
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Mette Husbyn
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-30 |
Mona Welschof
CTO | Chief Tech/Sci/R&D Officer | - | 13-09-30 |
Louise Stubbe
LAW | General Counsel | - | 21-12-31 |
Peter Fatum
PRN | Corporate Officer/Principal | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - | |
Chairman | 69 | 21-12-21 | |
Director/Board Member | 56 | - | |
Birgitte Volck
BRD | Director/Board Member | 61 | 21-05-04 |
Director/Board Member | 52 | - | |
Anders Tuv
BRD | Director/Board Member | 46 | - |
Elaine Sullivan
BRD | Director/Board Member | 63 | 22-05-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 326,546,444 | 179,598,448 ( 55.00 %) | 0 | 55.00 % |
Company contact information
Nykode Therapeutics ASA
Oslo Science Park Gaustadalléen 21
0349, Oslo
+47 22 95 81 93
http://www.nykode.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.13% | 384M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- VACC Stock
- Company Nykode Therapeutics